Abstract
Wilms' tumor gene 1 (WT1) is overexpressed in the majority (70–90%) of acute leukemias and has been identified as an independent adverse prognostic factor, a convenient minimal residual disease (MRD) marker and potential therapeutic target in acute leukemia. We examined WT1 expression patterns in childhood acute lymphoblastic leukemia (ALL), where its clinical implication remains unclear. Using a real-time quantitative PCR designed according to Europe Against Cancer Program recommendations, we evaluated WT1 expression in 125 consecutively enrolled patients with childhood ALL (106 BCP-ALL, 19 T-ALL) and compared it with physiologic WT1 expression in normal and regenerating bone marrow (BM). In childhood B-cell precursor (BCP)-ALL, we detected a wide range of WT1 levels (5 logs) with a median WT1 expression close to that of normal BM. WT1 expression in childhood T-ALL was significantly higher than in BCP-ALL (P<0.001). Patients with MLL-AF4 translocation showed high WT1 overexpression (P<0.01) compared to patients with other or no chromosomal aberrations. Older children (⩾10 years) expressed higher WT1 levels than children under 10 years of age (P<0.001), while there was no difference in WT1 expression in patients with peripheral blood leukocyte count (WBC) ⩾50 × 109/l and lower. Analysis of relapsed cases (14/125) indicated that an abnormal increase or decrease in WT1 expression was associated with a significantly increased risk of relapse (P=0.0006), and this prognostic impact of WT1 was independent of other main risk factors (P=0.0012). In summary, our study suggests that WT1 expression in childhood ALL is very variable and much lower than in AML or adult ALL. WT1, thus, will not be a useful marker for MRD detection in childhood ALL, however, it does represent a potential independent risk factor in childhood ALL. Interestingly, a proportion of childhood ALL patients express WT1 at levels below the normal physiological BM WT1 expression, and this reduced WT1 expression appears to be associated with a higher risk of relapse.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sugiyama H . Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 2001; 73: 177–187.
Sugiyama H . Wilms tumor gene WT1 as a tumor marker for leukemic blast cells and its role in leukemogenesis. Methods Mol Med 2002; 68: 223–237.
Scharnhorst V, van der Eb AJ, Jochemsen AG . WT1 proteins: functions in growth and differentiation. Gene 2001; 273: 141–161.
Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060–1067.
Menssen HD, Siehl JM, Thiel E . Wilms tumor gene (WT1) expression as a panleukemic marker. Int J Hematol 2002; 76: 103–109.
Wagner KD, Wagner N, Schedl A . The complex life of WT1. J Cell Sci 2003; 116 (Part 9): 1653–1658.
Little M, Holmes G, Walsh P . WT1: what has the last decade told us? Bioessays 1999; 21: 191–202.
Moorwood K, Salpekar A, Ivins SM, Hall J, Powlesland RM, Brown KW et al. Transactivation of the WT1 antisense promoter is unique to the WT1[+/−] isoform. FEBS Lett 1999; 456: 131–136.
Lee SB, Haber DA . Wilms tumor and the WT1 gene. Exp Cell Res 2001; 264: 74–99.
Loeb DM, Sukumar S . The role of WT1 in oncogenesis: tumor suppressor or oncogene? Int J Hematol 2002; 76: 117–126.
Caricasole A, Duarte A, Larsson SH, Hastie ND, Little M, Holmes G et al. RNA binding by the Wilms tumor suppressor zinc finger proteins. Proc Natl Acad Sci USA 1996; 93: 7562–7566.
Little NA, Hastie ND, Davies RC . Identification of WTAP, a novel Wilms' tumour 1-associating protein. Hum Mol Genet 2000; 9: 2231–2239.
Menke AL, Clarke AR, Leitch A, Ijpenberg A, Williamson KA, Spraggon L et al. Genetic interactions between the Wilms' tumor 1 gene and the p53 gene. Cancer Res 2002; 62: 6615–6620.
Karakas T, Miething CC, Maurer U, Weidmann E, Ackermann H, Hoelzer D et al. The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. Leukemia 2002; 16: 846–854.
Loeb DM, Korz D, Katsnelson M, Burwell EA, Friedman AD, Sukumar S . Cyclin E is a target of WT1 transcriptional repression. J Biol Chem 2002; 277: 19627–19632.
Idelman G, Glaser T, Roberts Jr CT, Werner H . WT1-p53 interactions in insulin-like growth factor-I receptor gene regulation. J Biol Chem 2003; 278: 3474–3482. E-pub 2002 Nov 19.
Carpenter B, Hill KJ, Charalambous M, Wagner KJ, Lahiri D, James DI et al. BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1. Regulation of the Wilms' tumour suppressor protein transcriptional activation domain. Mol Cell Biol 2004; 24: 537–549.
Niksic M, Slight J, Sanford JR, Caceres JF, Hastie ND . The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. Hum Mol Genet 2004; 13: 463–471. E-pub 2003 Dec 17.
Dallosso AR, Hancock AL, Brown KW, Williams AC, Jackson S, Malik K . Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours. Hum Mol Genet 2004; 13: 405–415. E-pub 2003 Dec 17.
Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA . The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. Embo J 2001; 20: 1897–1909.
Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 2002; 116: 409–420.
Loeb DM, Summers JL, Burwell EA, Korz D, Friedman AD, Sukumar S . An isoform of the Wilms' tumor suppressor gene potentiates granulocytic differentiation. Leukemia 2003; 17: 965–971.
Sugiyama H . Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia. Leuk Lymphoma 1998; 30: 55–61.
Bergmann L, Maurer U, Weidmann E . Wilms tumor gene expression in acute myeloid leukemias. Leuk Lymphoma 1997; 25: 435–443.
Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89: 1405–1412.
Niegemann E, Wehner S, Kornhuber B, Schwabe D, Ebener U . wt1 gene expression in childhood leukemias. Acta Haematol 1999; 102: 72–76.
Ozgen U, Anak S, Ozbek U, Sarper N, Eryilmaz E, Agaoglu L et al. wt1 gene expression in childhood acute leukemias. Acta Haematol 2000; 103: 229–230.
Chen Z . The possible role and application of WT1 in human leukemia. Int J Hematol 2001; 73: 39–46.
Kreuzer KA, Saborowski A, Lupberger J, Appelt C, Na IK, le Coutre P et al. Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias. Br J Haematol 2001; 114: 313–318.
Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115–2121.
Cilloni D, Saglio G . WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 2004; 112: 79–84.
Trka J, Kalinova M, Hrusak O, Zuna J, Krejci O, Madzo J et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002; 16: 1381–1389.
Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997; 90: 1217–1225.
Schmid D, Heinze G, Linnerth B, Tisljar K, Kusec R, Geissler K et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997; 11: 639–643.
Gaiger A, Linnerth B, Mann G, Schmid D, Heinze G, Tisljar K et al. Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol. Eur J Haematol 1999; 63: 86–93.
Chen JS, Coustan-Smith E, Suzuki T, Neale GA, Mihara K, Pui CH et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001; 97: 2115–2120.
Kletzel M, Olzewski M, Huang W, Chou PM . Utility of WT1 as a reliable tool for the detection of minimal residual disease in children with leukemia. Pediatr Dev Pathol 2002; 5: 269–275.
Siehl JM, Thiel E, Leben R, Reinwald M, Knauf W, Menssen HD . Quantitative real-time RT-PCR detects elevated Wilms tumor gene (WT1) expression in autologous blood stem cell preparations (PBSCs) from acute myeloid leukemia (AML) patients indicating contamination with leukemic blasts. Bone Marrow Transplant 2002; 29: 379–381.
Garg M, Moore H, Tobal K, Liu Yin JA . Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 2003; 123: 49–59.
Tamaki H, Mishima M, Kawakami M, Tsuboi A, Kim EH, Hosen N et al. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Int J Hematol 2003; 78: 349–356.
Magyarosy E, Varga N, Timar J, Raso E . Follow-up of minimal residual disease in acute childhood lymphoblastic leukemia by WT1 gene expression in the peripheral blood: the Hungarian experience. Pediatr Hematol Oncol 2003; 20: 65–74.
Barragan E, Cervera J, Bolufer P, Ballester S, Martin G, Fernandez P et al. Prognostic iplications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004; 89: 926–933.
Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P . WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single-centre study. Br J Haematol 2004; 125: 590–600.
Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698–1704.
Uzunel M, Jaksch M, Mattsson J, Ringden O, Brune M, Johansson JE et al. Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2003; 122: 788–794.
Ramirez O, Linares A, Trujillo ML, Caminos JE . WT1 mRNA in cerebrospinal fluid associated with relapse in pediatric lymphoblastic leukemia. J Pediatr Hematol Oncol 2003; 25: 453–458.
Renshaw J, King-Underwood L, Pritchard-Jones K . Differential splicing of exon 5 of the Wilms tumour (WTI) gene. Genes Chromosomes Cancer 1997; 19: 256–266.
Siehl JM, Reinwald M, Heufelder K, Menssen HD, Keilholz U, Thiel E et al. Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants. Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias. Ann Hematol 2004; 31: 31.
Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002; 99: 3272–3279.
Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132–2137.
Sugiyama H . Cancer immunotherapy targeting WT1 protein. Int J Hematol 2002; 76: 127–132.
Rosenfeld C, Cheever MA, Gaiger A . WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 2003; 17: 1301–1312.
Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Int J Hematol 2003; 78: 56–61.
Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.
Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia 2003; 17: 2474–2486.
van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901–1928.
Foroni L, Harrison CJ, Hoffbrand AV, Potter MN . Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Br J Haematol 1999; 105: 7–24.
Campana D . Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003; 121: 823–838.
Acknowledgements
We thank Katerina Muzikova from the laboratories of Department of Pediatric Hematology and Oncology, Prague, for the help with processing of samples, Tony Fitzgerald from Haughton Institute, St James's Hospital, Dublin and Marek Omelka from Deptartment of probability and mathematical statistics, Faculty of mathematics and physics of Charles University, Prague, for the help with statistical evaluation of the data. The collaboration of the Czech Pediatric Hematology Working Group centers is highly appreciated. This work has been supported by the HEA PRTLI, Children's Leukemia Research Project, Children's Medical and Research Foundation OLHSC, IGA (Czech Ministry of Health) 7439 and MSM (Czech Ministry of Education) 0021620813.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Boublikova, L., Kalinova, M., Ryan, J. et al. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 20, 254–263 (2006). https://doi.org/10.1038/sj.leu.2404047
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404047
Keywords
This article is cited by
-
Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant
Bone Marrow Transplantation (2022)
-
Preemptive interferon-α treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT
Scientific Reports (2020)
-
The prognostic significance of Wilms’ tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia
Annals of Hematology (2019)
-
Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases
Journal of Cancer Research and Clinical Oncology (2015)
-
Wilms tumor gene single nucleotide polymorphism rs16754 predicts a favorable outcome in children with acute lymphoblastic leukemia
Journal of Cancer Research and Clinical Oncology (2015)